

Year in Review: On Demand — Significance and Relevance of Recent Data Sets and Publications in the Management of Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The Phase III FLAURA study comparing first-line osimertinib to either erlotinib or gefitinib for advanced non-small cell lung cancer (NSCLC) with an EGFR tumor mutation demonstrated a significant improvement in progression-free survival (PFS) for patients who received osimertinib.
a. True
b. False
- _____ is an ALK inhibitor that is currently FDA approved for the treatment of metastatic NSCLC with an ALK rearrangement in patients who have experienced disease progression on or are intolerant to crizotinib.
a. Alectinib
b. Brigatinib
c. Lorlatinib
d. All of the above
- _____ is a promising investigational agent that targets TRK kinases in patients with NSCLC harboring an NTRK gene fusion.
a. LOXO-292
b. Larotrectinib
c. Both a and b
- The Phase III PACIFIC trial of durvalumab versus placebo for patients with locally advanced, unresectable NSCLC without disease progression after definitive platinum-based chemoradiation therapy demonstrated statistically significant improvement in _____ with durvalumab.
a. Overall survival
b. PFS
c. Both a and b
d. Neither a nor b
- Results of the Phase III KEYNOTE-042 trial demonstrated a significant improvement in overall survival with single-agent pembrolizumab compared to platinum-based chemotherapy as first-line treatment for advanced or metastatic NSCLC in patients with a PD-L1 tumor proportion score of _____.
a. 1% or greater
b. 20% or greater
c. 50% or greater
- Results of the Phase III IMpower150 trial of atezolizumab and/or bevacizumab added to carboplatin/paclitaxel as first-line therapy for metastatic nonsquamous NSCLC failed to demonstrate a statistically significant improvement in overall survival or PFS with the addition of atezolizumab and bevacizumab.
a. True
b. False
- The Phase III KEYNOTE-407 trial evaluating the addition of pembrolizumab to carboplatin with paclitaxel or *nab* paclitaxel as first-line therapy for metastatic squamous NSCLC demonstrated prolonged _____ with pembrolizumab.
a. Median overall survival
b. Median PFS
c. Both a and b
- Analysis of the impact of choice of taxane on outcomes for patients on the KEYNOTE-407 trial demonstrated that the treatment effect was _____ for patients who received paclitaxel versus those who received *nab* paclitaxel.
a. Greater
b. Lesser
c. Similar

Year in Review: On Demand — Significance and Relevance of Recent Data Sets and Publications in the Management of Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. Results of the Phase III CheckMate 227 trial evaluating the combination of nivolumab and ipilimumab versus chemotherapy for advanced NSCLC demonstrated a _____ with the combination for patients with a high tumor mutational burden.
- a. Significant improvement in overall response rate
 - b. Statistically significant improvement in PFS
 - c. Trend toward an improvement in overall survival
 - d. All of the above
 - e. Both a and b

10. To which of the following drug classes does rovalpituzumab tesirine belong?
- a. Antibody-drug conjugates
 - b. Anti-PD-1 antibodies
 - c. NTRK inhibitors
 - d. RET inhibitors